Table 1.

Main characteristics of the enrolled studies

Study	Study design	Diagnosis	Enrollment	Interventions	Course of treatment	Primary outcome measures
Dodick et al. [12]	Phase II	Episodic migraine	190 subjects	Galcanezumab 150 mg Placebo SC once every 14 days	12 weeks	Mean change from baseline in the number of migraine headache days (MHD)
Skljarevski et al. [13]	Phase IIb	Episodic migraine	414 subjects	Galcanezumab 5 mg/50 mg/120 mg/300 mg Placebo SQ once every 28 days	12 weeks	Mean change from baseline in the number of MHD
Detke et al. [16]	Phase III (REGAIN)	Chronic migraine	1,113 subjects	Galcanezumab 120 mg/240 mg Placebo SC once every 28 days	12 weeks	Overall mean change from baseline in the number of monthly MHD
Stauffer et al. [14]	Phase III (EVOLVE-1)	Episodic migraine	862 subjects	Galcanezumab 120 mg/240 mg Placebo SC once every 28 days	24 weeks	Overall mean change from baseline in the number of monthly MHD
Skljarevski et al. [13]	Phase III (EVOLVE-2)	Episodic migraine	986 subjects	Galcanezumab 120 mg/240 mg Placebo SC once every 28 days	24 weeks	Overall mean change from baseline in the number of monthly MHD